Louisiana Bill Would Create Psychedelic Therapy Research Initiative Using Opioid Settlement Funds

Louisiana could become the latest state to explore psychedelic-assisted therapy as a potential treatment for trauma, addiction, and traumatic brain injury under legislation introduced by State Senator Pat McMath. The bill, which advanced through committee this week, would establish a psychedelic therapy research initiative within the Louisiana Department of Health—funded in part by the state's unspent opioid settlement dollars.

The proposal arrives amid growing national interest in compounds like ibogaine, psilocybin, and MDMA as therapeutic tools for conditions that have proven resistant to conventional treatments. For veterans and first responders who have struggled to find relief through traditional psychiatric medications, the legislation represents a potential pathway to accessing treatments that have shown promise in early clinical trials and overseas programs.

From Battlefield to Healing

Nick Curtis, a veteran who traveled to Mexico last year for ibogaine and DMT-assisted therapy, has become a vocal advocate for the Louisiana initiative. Curtis and his father—a retired National Guard adjutant general—made the journey to Tijuana seeking treatment for traumatic brain injuries and service-connected PTSD. The experience, Curtis said, fundamentally altered both their trajectories.

"There was this warm massaging, vibrating sensation coming, like, almost like it was massaging my brain, the damaged areas back to life," Curtis described. His symptoms, including light sensitivity and persistent ringing in his ears, dissipated following the treatment. His father experienced similar relief from the emotional volatility that had plagued him since deployment.

The Curtises subsequently founded Awaken Warriors, a nonprofit organization dedicated to helping other veterans and first responders access similar retreats. Their advocacy has lent personal urgency to McMath's legislative push, providing lawmakers with concrete examples of how psychedelic therapy might address the mental health crisis affecting Louisiana's veteran population.

Funding Through Opioid Settlements

The bill's financial architecture reflects creative policymaking in an era of constrained state budgets. McMath proposes tapping Louisiana's opioid settlement funds—money flowing from litigation against pharmaceutical manufacturers and distributors responsible for fueling the addiction crisis. According to the senator, the vast majority of these funds remain unspent, presenting an opportunity to redirect resources toward innovative treatment approaches.

"A lot of those funds, in fact, the vast majority of those funds, have yet to be spent, and so, I think there's an avenue here we could create," McMath said in committee testimony. The approach has precedent: both Texas and Mississippi have enacted similar legislation supporting psychedelic-assisted treatment research, suggesting a regional momentum that Louisiana could join.

The opioid settlement mechanism carries symbolic weight beyond its fiscal utility. Using funds extracted from companies that profited from addictive pharmaceuticals to explore alternative treatments for addiction represents a form of restorative justice—redirecting resources from the entities that helped create the crisis toward potential solutions that conventional medicine has yet to fully embrace.

The Science Behind the Legislation

Psychedelic-assisted therapy operates on fundamentally different principles than standard psychiatric pharmacology. Rather than daily medication management, these protocols typically involve one or several supervised sessions with compounds that temporarily alter consciousness, combined with extensive preparatory and integration psychotherapy. The goal is not merely symptom suppression but a transformative experience that shifts underlying psychological patterns.

Research into ibogaine—the compound Curtis received—has shown particular promise for opioid use disorder. Derived from the root bark of the African iboga shrub, the substance appears to interrupt withdrawal symptoms and reduce drug cravings through mechanisms that remain incompletely understood. Clinical observations suggest it may work by resetting neural pathways associated with addiction, though rigorous controlled trials have been limited by regulatory barriers and funding constraints.

Psilocybin, the psychoactive component of certain mushrooms, has demonstrated efficacy in treating treatment-resistant depression and alcohol use disorder in studies at Johns Hopkins, NYU, and other major research institutions. MDMA-assisted therapy, despite recent FDA setbacks, showed remarkable results for PTSD in Phase 3 trials before regulatory concerns about study methodology delayed approval.

The Louisiana initiative would not immediately make these treatments available to patients. Instead, it would create a framework for research centers to coordinate studies, share data, and develop clinical protocols that could eventually inform broader treatment availability. This measured approach reflects lessons from other states that have moved more aggressively, sometimes outpacing the scientific evidence base.

Veterans as Catalysts

The veteran focus of Curtis's advocacy—and of psychedelic therapy research more broadly—reflects both the severity of the crisis and the political viability of serving those who have served. Military veterans experience PTSD at rates substantially higher than the general population, and the Department of Veterans Affairs has struggled to meet demand for mental health services. Over six thousand veterans die by suicide annually, a statistic that has fueled urgency around exploring any intervention that might reduce mortality.

Representative Morgan Luttrell of Texas, who testified before Congress about his own experience with psychedelic therapy for service-connected trauma, has become a prominent advocate for federal research acceleration. His personal story—combined with similar accounts from veterans across the political spectrum—has helped destigmatize compounds that remain classified as Schedule I substances with "no accepted medical use" under federal law.

The Louisiana bill specifically names veterans and first responders as priority populations for research participation, recognizing both their elevated need and their role as political advocates who can sustain funding and public support for the initiative.

Regulatory and Clinical Challenges

Establishing a state-level psychedelic research program involves navigating complex regulatory terrain. The compounds under consideration remain federally prohibited, meaning research must proceed through FDA-approved protocols with strict oversight. The Louisiana Department of Health would coordinate with academic medical centers, potentially including LSU Health and Tulane University School of Medicine, to ensure studies meet federal standards.

Clinical workforce development presents another challenge. Psychedelic-assisted therapy requires specialized training beyond standard psychiatric or psychological credentials. Therapists must learn to hold space for patients undergoing intense psychological experiences, manage potential adverse reactions, and provide integration support in the days and weeks following sessions. The bill does not specify funding for training programs, leaving open questions about how Louisiana would develop sufficient provider capacity.

Safety monitoring will be essential. While psychedelic compounds have shown remarkably low physiological toxicity in research settings, psychological risks—including the potential for destabilizing experiences in vulnerable individuals—require careful screening and clinical support. The initiative's success will depend in part on its ability to demonstrate that treatments can be delivered safely at scale, not merely in carefully controlled research environments.

A Shifting National Landscape

Louisiana's proposed initiative arrives at a moment of significant federal policy evolution. President Trump signed an executive order earlier this month directing the FDA to accelerate psychedelic research and expand patient access through multiple pathways, including the Right to Try Act for treatment-resistant patients. The order provides $50 million for state-level ibogaine research and creates a framework for Schedule I rescheduling of substances that complete Phase 3 clinical trials.

This federal momentum, combined with similar legislation in Texas and Mississippi, suggests that psychedelic therapy is transitioning from fringe alternative medicine to mainstream policy consideration. The compounds that fueled countercultural movements in the 1960s are now being embraced by conservative legislators as potential treatments for veterans and first responders—populations that command bipartisan respect.

For Louisiana, the bill represents an opportunity to position itself at the forefront of an emerging treatment paradigm while addressing urgent mental health needs among its veteran and first responder communities. Whether the research initiative produces clinically viable treatments or merely adds to the growing body of preliminary evidence will depend on execution, funding continuity, and the scientific rigor of the studies it enables.

The measure now proceeds to the full Senate for consideration, with advocates hoping for passage before the legislative session adjourns.